Behcet's syndrome


Yazici H., Yurdakul S., HAMURYUDAN V.

Current Opinion in Rheumatology, vol.11, no.1, pp.53-57, 1999 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 1
  • Publication Date: 1999
  • Doi Number: 10.1097/00002281-199901000-00009
  • Title of Journal : Current Opinion in Rheumatology
  • Page Numbers: pp.53-57

Abstract

There have not been any breakthroughs in understanding of the pathogenesis of Behcet's syndrome within the past year. We still do not know the meaning of the HLA-B51 association. The role of T cells in pathogenesis is still undefined, and it is not yet clear whether an extrinsic antigen or antigens produces the disease. Likewise the role of the neutrophil in pathogenesis is under scrutiny. More pediatric cases are being described. We are beginning to have a better understanding of central nervous system involvement, the prime pathology of which might not be vasculitis. Azathioprine, not a panacea, is nevertheless effective for long-term management. Thalidomide has clearly been shown to be effective in mucocutaneous disease even at a dose of 100 mg/d. However, relapses are seen with cessation of therapy.